These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 32006615)

  • 1. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.
    Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Kuan WL; Evans JR; Breen DP; Cummins G; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
    Brain Behav Immun; 2020 Jul; 87():473-488. PubMed ID: 32006615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Nissen SK; Ferreira SA; Nielsen MC; Schulte C; Shrivastava K; Hennig D; Etzerodt A; Graversen JH; Berg D; Maetzler W; Panhelainen A; Møller HJ; Brockmann K; Romero-Ramos M
    Mov Disord; 2021 Apr; 36(4):963-976. PubMed ID: 33332647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson's disease and cognition.
    Konstantin Nissen S; Farmen K; Carstensen M; Schulte C; Goldeck D; Brockmann K; Romero-Ramos M
    Brain Behav Immun; 2022 Mar; 101():182-193. PubMed ID: 35026420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
    Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
    J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease.
    Su Y; Shi C; Wang T; Liu C; Yang J; Zhang S; Fan L; Zheng H; Li X; Luo H; Zhang S; Hu Z; Fan Y; Hao X; Zhang C; Song B; Mao C; Xu Y
    J Neurol; 2022 Dec; 269(12):6386-6394. PubMed ID: 35895134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
    Gardai SJ; Mao W; Schüle B; Babcock M; Schoebel S; Lorenzana C; Alexander J; Kim S; Glick H; Hilton K; Fitzgerald JK; Buttini M; Chiou SS; McConlogue L; Anderson JP; Schenk DB; Bard F; Langston JW; Yednock T; Johnston JA
    PLoS One; 2013; 8(8):e71634. PubMed ID: 24058406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.
    White AJ; Wijeyekoon RS; Scott KM; Gunawardana NP; Hayat S; Solim IH; McMahon HT; Barker RA; Williams-Gray CH
    Front Neurol; 2018; 9():946. PubMed ID: 30524354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut.
    Gorecki AM; Anyaegbu CC; Anderton RS
    Transl Neurodegener; 2021 Nov; 10(1):47. PubMed ID: 34814947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease.
    Bartl M; Xylaki M; Bähr M; Weber S; Trenkwalder C; Mollenhauer B
    Neurobiol Dis; 2022 Aug; 170():105744. PubMed ID: 35513230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis.
    Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
    Front Neurol; 2018; 9():870. PubMed ID: 30386290
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
    Heidari A; Yazdanpanah N; Rezaei N
    J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson's Disease in a Chinese Population.
    Peng G; Qiu J; Liu H; Zhou M; Huang S; Guo W; Lin Y; Chen X; Li Z; Li G; Zhang W; Zhang Y; Li X; Wu Z; Wei L; Yang X; Zhu X; Mo M; Xu P
    J Mol Neurosci; 2020 Feb; 70(2):294-301. PubMed ID: 31833018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Blood Monocyte Functions in Parkinson's Disease.
    Nissen SK; Shrivastava K; Schulte C; Otzen DE; Goldeck D; Berg D; Møller HJ; Maetzler W; Romero-Ramos M
    Mov Disord; 2019 Nov; 34(11):1711-1721. PubMed ID: 31449711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.
    Forsyth CB; Shannon KM; Kordower JH; Voigt RM; Shaikh M; Jaglin JA; Estes JD; Dodiya HB; Keshavarzian A
    PLoS One; 2011; 6(12):e28032. PubMed ID: 22145021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
    Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.